CompletedPhase 2NCT00775463
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine
Studying Diffuse cutaneous systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- United Therapeutics
- Principal Investigator
- James Seibold, MDScleroderma Research Consultants LLC, Avon, CT,
- Intervention
- treprostinil diethanolamine(drug)
- Enrollment
- 148 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2011
Study locations (30)
- University of Alabama - Arthritis Clinical Intervention Program, Birmingham, Alabama, United States
- Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
- UCLA, Los Angeles, California, United States
- Stanford University School of Medicine/Palo Alto VA Health Care System, Palo Alto, California, United States
- Denver Medical Center, Aurora, Colorado, United States
- University of Connecticut Health Center, Farmington, Connecticut, United States
- Georgetown University, Washington D.C., District of Columbia, United States
- Northwestern University - Feinberg School of Medicine, Chicago, Illinois, United States
- University of Indiana School of Medicine, Indianapolis, Indiana, United States
- Johns Hopkins University - Division of Rheumatology, Baltimore, Maryland, United States
- Boston University School of Medicine, Boston, Massachusetts, United States
- University of Michigan Scleroderma Program, Ann Arbor, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- UMDNJ Clinical Research Center, New Brunswick, New Jersey, United States
- North Shore-LIJ Health System, Lake Success, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00775463 on ClinicalTrials.govOther trials for Diffuse cutaneous systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07473154Controlling Hyperactive Immunity With Long-lived LymphocytesQuell Therapeutics Limited
- RECRUITINGPHASE1, PHASE2NCT06947473Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.Beijing GoBroad Hospital
- RECRUITINGPHASE2NCT05029336Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesStephan Grupp MD PhD
- RECRUITINGPHASE2NCT07047690A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisGalderma R&D
- RECRUITINGPHASE2NCT07287670EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Mediar Therapeutics
- RECRUITINGNCT07256418Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaCentre Hospitalier Universitaire Dijon
- RECRUITINGPHASE1NCT07295847A Study of AZD0120 in Autoimmune DiseasesAstraZeneca
- RECRUITINGNANCT07292961Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With SclerodermaHacettepe University